Enanta Pharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Enanta Pharmaceuticals, Inc.
Deal Watch: Roche, PhoreMost Enter Into Multi-Target Collaboration
Plus deals with Synaffix/Emergence, Helsinn/Juniper and Sanyou/Shanghai KangaBio, while Takeda/Finch and Dong-A/Beactica ended prior collaborations.
Cardio Catch-Up: Arga, HeartPoint Plan First-In-Human Trials Of Novel Devices; Medtronic And Edwards Announce Product Launches, And More
The second half of summer is usually a slow time for news about cardiac technology innovations because there are not many major conferences. But there was still plenty of innovation news coming from both small and big cardiovascular device companies in July and August.
Gilead Gets Lenacapavir To EU Approval For HIV Salvage Therapy, Awaits FDA’s Call
A first-in-class capsid inhibitor, lenacapavir is a linchpin of Gilead’s long-term strategy in HIV treatment and prevention, but has faced regulatory setbacks in the US.
Enanta’s Path Forward Uncertain After RSV Failure
The US biotech’s RSV treatment candidate has failed a Phase II study in low-risk patients leaving some experts skeptical of its hopes for potential improved performance in a high-risk setting.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.